Analysis of Patients With Common PTCL Subtypes From a Phase II Study of Romidepsln In Relapsed or Refractory PTCL

摘要

Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous group of lymphomas associated with poor responses to chemotherapy, high relapse rates, and poor long-term survival. There is no standard of care for the treatment of PTCL. Romidep-sin is a histone deacetylase (HDAC) inhibitor that is approved in the United States for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy and patients with PTCL who have received at least 1 prior therapy.